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Background: Although most of the literature about health-related quality of life (HRQoL) focuses on breast cancer
patients, few studies compared the HRQoL in disease-free breast cancer survivors with that of the general population.
Materials and methods: We administered the European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire Core 30 and Quality of Life Questionnaire Breast Cancer Module, McGill Quality of Life
Questionnaire, Beck Depression Inventory, and Brief Fatigue Inventory to 1933 disease-free survivors for over 1 year
after being diagnosed with stage 0 to III breast cancer. We performed multivariate-adjusted analyses in all HRQoL
comparisons.
Results: The scores for some HRQoL scales were comparable for both disease-free breast cancer survivors and the
general female population; however, there was clinically significant difference in cognitive and social functioning,
fatigue, insomnia, and financial difficulties between the two groups. Radiotherapy and systemic adjuvant therapy
variables did not limit the HRQoL. Demographic characteristics such as age, time since surgery, and comorbidity were
associated with some HRQoL scales and fatigue and depression were associated with almost all HRQoL scales.
Conclusions: Disease-free survivors of breast cancer had good HRQoL, which was less affected by the type of
treatment than it was by demographic characteristics, time since surgery, comorbidity, fatigue, and depression.
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introduction
Breast cancer patients are the largest group of female cancer
survivors worldwide [1]. As their number has grown, concern
has increasingly been directed to treatment-related sequelae and
their effects on health-related quality of life (HRQoL) [2]. If we
could identify factors that increase cancer survivors’ risk for
diminished HRQoL, we could develop strategies to overcome
those factors and design appropriate intervention programs [3].
Although most of the literature about HRQoL focuses on breast
cancer patients [3–5], few studies have concentrated specifically
on comparison of the long-term HRQoL in disease-free breast
cancer survivors with that of the general population.
The Korean National Cancer Center initiated the Breast
Cancer Quality Care Study, which focused on treatment
experiences and health outcomes for women diagnosed and
treated for cancer in Korea. As part of that study, we compared
the HRQoL of disease-free breast cancer survivors with that
of the general population and sought to evaluate the impact of
demographic and treatment-related characteristics and of
health status on survivors’ HRQoL.
materials and methods
study design and subject recruitment
We identified women who had undergone primary curative surgery for
breast cancer between 1993 and 2002 in five hospital-based breast cancer
registries in Korea. The registries contained information about stage, type
of surgery, history of cancer therapy, and other clinical characteristics,
such as recurrence and date of last follow-up. Women were eligible to
participate if they (i) had a past diagnosis of breast cancer (stage 0, I, II,
or III), (ii) were on no current cancer therapy other than tamoxifen, (iii)
were currently free of the disease, and (iv) had no other history of cancer.
Eligible patients were contacted by telephone, and those who agreed to
participate were sent the questionnaire with consent forms and a postage-
paid return envelope. Subjects who did not return a questionnaire within
1 month received a reminder card and a telephone call. After reviewing
the medical information from the registry, we excluded subjects who had
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recurrent cancer and were receiving cancer therapy. Then, reviewing the
patient-reported questionnaire, we excluded subjects who had recurrent
cancer and were receiving cancer therapy other than hormonal therapy at
the time of the survey. If clinical and self-reported data were not
consistent, we gave precedence to the clinical data.
We compared the HRQoL of breast cancer survivors—obtained with the
European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire Core 30 (EORTC QLQ-C30), Quality of Life
Questionnaire Breast Cancer Module (QLQ-BR23), and the McGill Quality
of Life Questionnaire (MQoL) existential and support scales—with that of
the general female population. The reference data were derived from
a representative sample of the Korean adult population, comprising
500 men and 500 women selected by a nationwide random route technique.
A trained interviewer visited each patient’s home and explained the purpose
of study. As breast cancer affects mainly women, we used only data for
women in the general population sample for all comparisons in this
study. This group completed the self-reported questionnaire in the
presence of an interviewer who was there to explain the purpose of study,
but like the survivors, they completed the questionnaire for themselves
without the interviewer’s assist. The institutional review board of the
National Cancer Center reviewed and approved the protocol of our study.
instruments
Patients completed a questionnaire that covered demographic and clinical
characteristics and a number of standardized instruments designed to assess
HRQoL, existential QoL, fatigue, and depression. The EORTC QLQ-C30 is
a 30-item cancer-specific questionnaire for assessing the general HRQoL
of cancer patients [6]. The questionnaire incorporates five functioning
domains (physical, role, cognitive, emotional, and social), three symptom
scales (fatigue, pain, and nausea and vomiting), global health and overall
HRQoL scales, and several single items that assess additional symptoms
commonly reported by cancer patients (e.g., dyspnea, appetite loss, sleep
disturbance, constipation, and diarrhea) and the perceived financial impact
of disease and treatment.
The EORTC QLQ-BR23 was designed to assess the impact of common
breast cancer treatment modalities (surgery, chemotherapy, radiotherapy, or
hormonal treatment) upon women’s well-being [7]. The module
incorporates 23 questions grouped into the functioning scale (i.e., body
image, sexuality, and future perspective) and the symptom scales and single
item to assess systemic side-effects, arm symptoms, breast symptoms, and
hair loss. For this study we used a combined form of the QLQ-C30 and
QLQ-BR23, the Korean version of which has been validated [8]. The
existential and support subscales of the MQoL were also administered. The
MQoL is a multidimensional HRQoL questionnaire whose validity and
reliability have been established in patients with chronic illness [9]. The
existential and support subscales focus on the individual’s ability to find
meaning in existence and achieve goals, and they also cover issues of
support. Each of these multiple-item scales was scored from 0 to 10, with
a higher score representing better HRQoL. The MQoL was translated into
Korean by the forward–backward translation process and was pilot tested
with the original author’s approval.
The Brief Fatigue Inventory (BFI) was used to evaluate the survivors’
experience of fatigue, one of the most common long-term effects of
treatment [10, 11]. The Korean version of the BFI consists of a one-page
fatigue assessment tool that contains nine items, each measuring the severity
of fatigue on a 0 to 10 scale. The first three items assess current level of
fatigue and the worst and usual fatigue in the preceding 24 hours. Six
items assess the extent to which fatigue has interfered with different
aspects of life, such as work or social relations, during the preceding
24 hours. The global score for the BFI is calculated as the mean value of
those nine items; a higher score represents more severe fatigue.
Depression was assessed using the Beck Depression Inventory (BDI). The
BDI, which was originally designed to measure the depth or intensity of
depression in psychiatric patients, evaluates 21 symptoms of depression.
Each symptom is rated on a four-point intensity scale. The scores are
added, yielding a total ranging from 0 to 63; a higher score represents more
severe depression [12]. The Korean version of the BDI has been validated.
In addition to the above measures, the full survey instrument also
included items concerning treatment experience, work problems, and regret
and satisfaction about treatment decisions. We will publish the results of
those aspects of the study in the future. Feasibility and comprehensibility of
the survey instrument were pretested with 15 breast cancer survivors.
Deceased
N = 971
(9.0%)
Not Contacted
N = 5,386
(49.9%)
Refused
N = 1,447
(32.6%)
Did Not Return Questionnaire
N = 589
(19.7%)
Questionnaire Incomplete
N = 318
(13.3%)
Questionnaire Ineligible
N = 152
(6.3%)
Quesionnaire Complete
N = 1,933
(80.4%)
Returned Questionnaire
N = 2,403
(80.3%)
Consented
N = 2,992
(67.4%)
Contacted
N = 4, 439
(41.1%)
Invitation by Telephone
N = 10.796
Figure 1. Recruitment response to mailed invitations and survey questionnaires.
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statistical methods
We scored the QLQ-C30 and QLQ-BR23 items according to the EORTC
scoring manual [13]. We linearly transformed the QLQ-C30 and QLQ-BR23
data to yield scores from 0 to 100; a higher score represented a better level
of functioning or a higher level of symptoms. We handled incomplete
questionnaires according to the developers’ recommendations. We did
not use BFI, BDI, or MQoL scales with missing values.
We used descriptive statistics for clinical, socioeconomic, and therapeutic
variables and t- and chi-square tests. We compared breast cancer survivors
with the general population controls on the basis of multivariate (age,
marital status, education, religion, and employment status)-adjusted
HRQoL means and the proportion of ‘problematic groups’ in each HRQoL
scale. We defined a problematic group as one with a global HRQoL or
functioning scale score of 33 or less and a symptom scale score of 66 or more
on the QLQ-C30 or QLQ-BR23 [14]. Since these groups differed by
demographic characteristics (age, marital status, education, religion,
employment status, menopause, time since surgery, and comorbidity), we
also compared multivariate-adjusted means of HRQoL between treatment
subgroups. We used analysis of covariance with a generalized linear model to
determine significant differences between groups. We used multiple
regression analysis to examine the impact of demographic and clinical
characteristics on HRQoL. Because of multiple comparisons, we considered
a P value less than 0.01 to be statistically significant in univariate and
multivariate analysis, and we defined a ‘clinically significant’ difference in
HRQoL as a 10-point difference in mean score [13, 14]. We used the
multiple R2 coefficients to estimate the percentage of variability of the
dependent variable accounted for by all covariates in the regression model.
All statistical tests were two sided.
results
subjects and recruitment results
We identified 10 796 potentially eligible breast cancer survivors
from the participating registries. Of them, 971 (9.0%) died. We
made multiple attempts to contact the others by postcard or
telephone but were not able to reach 5386 (49.9%) of them;
the most frequent reason for contact failure was a change of
address or telephone number. Of the 4439 women who were
contacted, 32.6% refused to participate. The reasons given most
frequently were that the survey was inconvenient, that it took
too long to complete, or that the patient felt too ill. Of the
2992 women who consented to participate, 2403 (80.3%)
returned the questionnaire. Of them, we excluded 152 women
who had recurrent cancer or were receiving cancer therapy at the
time. After we reviewed the questionnaires for completeness,
1933 women remained in the study (Figure 1).
Whereas participants were more likely than nonparticipants
to have received breast-conserving surgery (BCS) (P < 0.001),
there were no other major differences between the groups with
respect to age or type of treatment received (chemotherapy,
radiation therapy, or hormone therapy). The median follow-up
was 50 months from the time of the surgery (range, 16–143
months).
Table 1 presents the baseline sociodemographic
characteristics of the participants in the mastectomy group
and the BCS group at the time of the survey.
Table 1. Demographic and clinical characteristics of participants
Characteristics BCS (N = 634) Mastectomy (N = 1299) P
No. of patients % No. of patients %
Age, years <0.01
Mean (SD) 46.6 (9.4) 47.8 (9.2)
Marital status (N = 1891) NS
Married 527 85.1 1078 85.8
Education (N = 1889) <0.001
‡High school graduate 471 76.5 865 68.0
Religion (N = 1887) NS
Christian 226 36.6 468 36.9
Buddhist 179 29.0 373 29.4
Catholic 110 17.8 225 17.7
Nonreligious 90 14.6 192 15.1
Others 13 2.1 11 0.9
Employment status (N = 1781) <0.01
Unemployed 377 64.7 862 72.0
Menopausal status (N = 1886) <0.001
Postmenopausal 460 74.7 1042 82.1
Time since surgery, months <0.001
Median (range) 44 (15–135) 53 (16–143)
Comorbidity <0.01
£1 557 87.9 1068 82.2
‡2 77 12.1 231 17.8
Experience of treatments
Chemotherapy (yes) 342 57.3 799 64.9 <0.01
Radiotherapy (yes) 504 82.4 229 18.4 <0.001
Hormone therapy (yes) 266 48.0 575 48.1 NS
BCS, breast-conserving surgery; SD, standard deviation; NS, not significant.
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The proportion of missing data for each of the instruments
was as follows: QLQ-C30, 2.3%; QLQ-BR23, 5.1%; MQoL,
4.0%; BFI, 2.3%; and BDI, 2.9%.
HRQoL according to types of treatment
Although women who received no systemic chemotherapy had
statistically significantly better social functioning, less insomnia,
and fewer financial difficulties, measured by the QLQ-C30, they
did not show clinically significant difference (Table 2). The
QLQ-BR23, MQoL, BFI, and BDI showed no differences among
groups by adjuvant treatment. We also compared survivors
with or without radiotherapy by type of surgery (Table 3).
Among the BCS group, the QLQ-C30, QLQ-BR23, MQoL,
BFI, and BDI did not show any difference between patients
who underwent radiotherapy and those who did not. Among
mastectomy patients, only social functioning and financial
difficulties, measured by the QLQ-C30, were significantly
better in women who received no radiotherapy, but these also
did not show clinically significant difference.
predictors of HRQoL in multivariate analysis
In multivariate analysis, chemotherapy, radiotherapy, and
hormone therapy had little impact on HRQoL, but mastectomy
compared with BCS was associated with lower social
functioning and poorer body image (Table 4). The type of
surgery had an impact on body image. Women who had
undergone mastectomy reported a clinically significant
poorer body image than women who had BCS (least-squares
mean, 43.9 versus 63.2). It had no clinically significant
impact, however, on social functioning (least-squares mean
Table 2. LS mean valuesa of EORTC QLQ-C30, QLQ-BR23, MQoL, BFI, and BDI scales in breast cancer survivors by adjuvant teatment
Variable Surgery, chemotherapy,
and hormone therapy
(N = 593)
Surgery and
hormone therapy
(N = 223)
Surgery and
chemotherapy
(N = 488)
Surgery
alone
(N = 400)
LS mean SE LS mean SE LS mean SE LS mean SE
EORTC QLQ-C30
Global health status/QoL 66.46 1.01 69.22 1.63 64.57 1.08 67.06 1.23
Physical functioning 77.18 0.71 79.80 1.16 77.42 0.76 79.54 0.87
Role functioning 74.31 1.04 78.56 1.69 74.31 1.12 76.84 1.28
Emotional functioning 71.80 1.01 74.84 1.64 72.59 1.09 76.00 1.25
Cognitive functioning 71.24 0.95 75.03 1.56 73.11 1.03 73.68 1.17
Social functioningb 77.53 1.10 83.3 1.78 78.75 1.18 82.59 1.35
Fatigue 37.56 1.01 35.66 1.65 36.56 1.10 34.70 1.25
Nausea and vomiting 9.55 0.70 8.36 1.14 9.14 0.76 6.42 0.38
Pain 20.00 0.95 17.06 1.55 21.60 1.03 19.22 1.17
Dyspnea 18.63 1.08 15.60 1.75 18.01 1.16 16.72 1.33
Insomniab 27.4 1.33 23.67 2.15 23.42 1.43 20.44 1.63
Appetite loss 10.32 0.93 7.78 1.51 12.12 1.00 8.41 1.14
Constipation 23.13 1.25 19.08 2.02 19.98 1.35 20.20 1.53
Diarrhea 8.67 0.82 10.54 1.32 9.38 0.88 8.52 1.00
Financial difficultiesb 25.17 1.28 16.9 2.09 25.62 1.38 20.03 1.58
EORTC QLQ-BR23
Body image 47.17 1.43 52.61 2.32 50.00 1.55 51.25 1.75
Sexual functioning 23.17 1.07 24.13 1.74 22.12 1.17 24.06 1.34
Sexual enjoyment 40.22 2.01 42.04 3.24 41.37 2.14 40.44 2.50
Future perspective 42.45 1.40 47.38 2.28 44.60 1.52 47.92 1.73
Systemic therapy side-effect 27.77 0.80 25.57 1.29 26.31 0.86 25.10 0.97
Breast symptoms 19.14 0.82 16.81 1.33 19.13 0.88 16.80 1.01
Arm symptoms 29.13 1.10 26.07 1.79 29.06 1.19 27.35 1.35
Upset by hair loss 41.28 2.15 34.16 3.72 41.05 2.38 38.12 2.96
MQoL
Existential subscale 7.21 0.09 7.34 0.14 6.98 0.10 7.24 0.11
Support subscale 7.49 0.09 7.44 0.15 7.16 0.10 7.51 0.11
BFI total score 33.59 0.89 32.69 1.46 34.31 0.97 33.52 1.10
BDI total score 14.20 0.38 13.81 0.62 14.48 0.41 13.60 0.47
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; BR23, breast cancer module;
MQoL, McGill Quality of Life Questionnaire; BFI, Brief Fatigue Inventory; BDI, Beck Depression Inventory; QoL, quality of life; LS, least squares;
BCS, breast-conserving surgery; SE, standard error. P values are from analysis of covariance with a generalized linear model.
aAdjusted for age, marital status, education, religion, employment status, menopausal status, time since surgery, and comorbidity.
bP <0.01.
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79.0 versus 81.3) (data not shown). With increasing age,
breast cancer survivors reported better social and emotional
functioning and future perspectives but poorer physical and
sexual functioning and diminished sexual enjoyment.
Multivariate analysis also revealed that comorbidity had
a negative effect on global HRQoL; on physical, role, and
cognitive functioning; and on future perspectives, but all
these factors improved with time. Menopausal status was
related to sexual functioning, sexual enjoyment, and
existential well-being (MQoL). Those who practiced
a religion had higher scores on the existential and support
subscales than those who did not. Interestingly, depression
and fatigue emerged as the strongest predictors of almost all
HRQoL studies in multivariate analyses.
comparison of HRQoL between breast cancer
survivors and the general population
Figures 2 and 3 present the HRQoL data for the breast cancer
survivors and general population groups. Breast cancer
survivors and general population subjects showed the similar
multivariate-adjusted mean scores for global HRQoL, nausea/
vomiting, dyspnea, appetite loss, and diarrhea on the QLQ-C30,
all scales of the QLQ-BR23, and the MQoL existential and
support scales. In contrast, breast cancer survivors showed
poorer QLQ-C30 scores for all functioning scales and the
remaining symptoms. We found clinically significant differences
among breast cancer survivors with respect to QLQ-C30 scales
of cognitive functioning, social functioning, financial
difficulties, fatigue, and insomnia.
Table 3. LS mean valuesa of EORTC QLQ-C30, QLQ-BR23, MQoL, BFI, and BDI scales in breast cancer survivors with or without radiotherapy by
type of surgery
Variable BCS (N = 612) Mastectomy (N = 1245)
Without radiotherapy
(N = 108)
With radiotherapy
(N = 504)
Without radiotherapy
(N = 1016)
With radiotherapy
(N = 229)
LS mean SE LS mean SE LS mean SE LS mean SE
EORTC QLQ-C30
Global health status/QoL 62.70 2.63 67.88 1.15 66.28 0.74 64.48 1.62
Physical functioning 76.48 1.79 79.21 0.79 78.00 0.52 76.21 1.13
Role functioning 72.56 2.68 77.48 1.17 75.34 0.76 73.37 1.66
Emotional functioning 72.36 2.63 74.36 1.15 73.23 0.75 72.79 1.64
Cognitive functioning 74.63 2.40 72.72 1.04 73.60 0.69 72.01 1.51
Social functioningb 81.62 2.49 81.99 1.09 80.65 0.82 73.54 1.78
Fatigue 40.85 2.77 36.03 1.20 35.93 0.73 36.97 1.59
Nausea and vomiting 7.74 1.56 7.61 0.68 8.37 0.54 9.68 1.18
Pain 19.64 2.34 18.56 1.02 19.94 0.72 20.35 1.57
Dyspnea 19.88 2.54 15.60 1.11 17.15 0.80 20.90 1.76
Insomnia 23.27 3.61 26.48 1.57 22.98 0.95 24.02 2.08
Appetite loss 11.32 2.32 9.38 1.02 9.63 0.68 12.95 1.48
Constipation 20.78 3.29 21.0 1.44 21.00 0.89 18.73 1.95
Diarrhea 7.80 2.03 9.15 0.89 8.92 0.59 7.89 1.28
Financial difficultiesc 23.35 3.04 20.15 1.33 22.90 0.97 29.91 2.10
EORTC QLQ-BR23
Body image 63.72 3.40 63.69 1.48 42.88 1.02 48.43 2.23
Sexual functioning 22.85 2.77 24.41 1.18 22.85 0.79 21.04 1.73
Sexual enjoyment 50.33 5.51 43.26 2.16 39.34 1.43 38.35 3.43
Future perspective 46.26 3.64 45.83 1.58 44.82 1.04 45.49 2.26
Systemic therapy side-effect 27.08 2.02 26.09 0.88 26.30 0.58 25.79 1.27
Breast symptoms 17.18 2.07 17.98 0.91 18.16 0.60 21.12 1.32
Arm symptoms 26.23 2.73 27.01 1.19 28.00 0.82 33.01 1.78
Upset by hair loss 41.08 6.57 41.68 2.58 37.65 1.59 38.24 3.31
MQoL
Existential subscale 6.88 0.22 7.22 0.09 7.15 0.067 7.11 0.14
Support subscale 7.16 0.24 7.38 0.10 7.41 0.07 7.33 0.15
BFI total score 35.71 2.30 33.64 1.01 33.33 0.65 33.75 1.42
BDI total score 14.53 0.90 13.58 0.40 14.27 0.29 14.38 0.63
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; BR23, breast cancer module;
MQoL, McGill Quality of Life Questionnaire; BFI, Brief Fatigue Inventory; BDI, Beck Depression Inventory; BCS, breast-conserving surgery; QoL, quality of
life; LS, least squares; SE, standard error. P values are from analysis of covariance with a generalized linear model and are for the comparison between women
who received radiotherapy and those who received no radiotherapy by type of surgery.
aAdjusted for age, marital status, education, religion, employment status, menopausal status, time since surgery, and comorbidity.
bP < 0.001.
cP < 0.01.
Annals of Oncology original article
Volume 18 | No. 1 | January 2007 doi:10.1093/annonc/mdl333 | 177
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on June 1, 2014
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
Table 4. Beta coefficients for EORTC QLQ-30, QLQ-BR23, and MQoL using multiple regression including demographic and clinical variables
Variables Global health
status/QoL
Physical
functioning
Role
functioning
Emotional
functioning
Cognitive
functioning
Social
functioning
Body
image
Sexual
functioning
Sexual
enjoyment
Future
perspective
Existential
subscale
Support
subscale
Age, years – 0.18a – 0.25a – 0.32a – 0.38b 0.60a 0.46b – –
Married – – – – – – – 9.38b – – – –
‡High school 2.78a 3.36 b – 4.01a – 4.68a – – – – – –
Religious – – – – – 6.32b – – – – 0.39a 0.47a
Employed – 2.85a 4.44b – – – – – – – – –
Postmenopausal – – – – – – – 8.19b 9.65a – 0.34a –
Time since surgery, year – 0.48a 0.70a 0.79b – 0.62a – – – 1.46b – –
Comorbidity 4.09a 2.61a 4.17a – 3.76a – – – – 5.47a – –
Mastectomy – – – – _ 4.98a 16.3b – – – – –
Chemotherapy – – – – – – – – – – – –
Radiotherapy – – – – – – – – – – – –
Antihormonal therapy – – – – – – – – – – – –
BFI total score 0.54b 0.32b 0.48b 0.28b 0.30b 0.27b 0.19b – – 0.17a 0.01b 0.01b
BDI total score 0.67b 0.33b 0.55b 1.22b 0.68b 0.81b 1.32 b 0.37b 0.52a 1.27b 0.13b 0.12b
Adjusted R2 0.47 0.33 0.35 0.44 0.27 0.25 0.29 0.11 0.19 0.21 0.42 0.29
No. of patients 1349 1335 1344 1343 1346 1331 1343 1242 465 1341 1336 1321
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; BR23, breast cancer module; MQoL, McGill Quality of Life Questionnaire;
QoL, quality of life. P values are from analysis of covariance with a generalized linear model.
aP < 0.01.
bP < 0.001.
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Figure 2. Least-squares mean scores (adjusted for age, marital status, education, religion, employment status, menopausal status, and comorbidity) of
EORTC QLQ-C30 and problematic proportion among the breast cancer survivors population (BP) and general population (GP). EORTC QLQ-C30,
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; QoL, Quality of life. Problematic in global QoL
and functioning indicates the score is 33 or less and problematic in symptoms indicates the score is above 66 on a scale of 0–100.
aP < 0.001 from analysis of covariance with a generalized linear model and are for the comparison between breast cancer survivors and
general population.
bP < 0.001 from chi squares for the comparison between breast cancer survivors and general population and are two sided.
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Breast cancer survivors had a higher proportion of
problematic groups than the general population in the physical,
role, emotional, social, and cognitive functioning scales of
QLQ-C30. Of the symptom scales, breast cancer survivors had
a higher proportion of problematic groups with respect to
fatigue, insomnia, constipation, and financial problems. The
two groups did not differ significantly in their proportion of
problematic groups according to the QLQ-BR23.
discussion
This large population-based study of Korean women suggests
that almost all HRQoL scale scores—including overall QoL and
some functioning and existential well-being scales—and those
of many symptoms are comparable for disease-free breast
cancer survivors and women in the general population who
have never confronted cancer. There were clinically significant
differences, however, in cognitive and social functioning,
fatigue, insomnia, and financial difficulties. Thus, to improve
the HRQoL of cancer survivors, healthcare providers should
focus more on these effects in follow-up services.
Our multiple regression analysis of the data obtained from the
QLQ-C30, its breast cancer-specific module (QLQ-BR23),
MQoL, BDI, and BFI confirmed previous observations that
beyond the first year after a diagnosis of breast cancer, the
survivor’s long-term HRQoL, except for body image, is more
likely influenced by demographic characteristics than by the
type of surgery [3, 15–18]. These findings lend further weight
to the argument that BCS is a better treatment choice than
mastectomy because treatment-related mortality and long-term
survival are similar for both procedures but a better body image
is a significant predictor of a woman being sexually active and
is also associated with sexual satisfaction [17].
The goal of postoperative therapy is to reduce the rate of
relapse and improve survival rates [18, 19]. In this study,
systemic adjuvant treatment caused no clinically significant
limitations in global HRQoL, functioning, existential well-
being, or symptoms, nor did radiotherapy cause clinically
significant HRQoL limitations. These findings agree with those
of a recent Chinese study [3] but differ with findings from other
studies suggesting that survivors who do not receive adjuvant
therapy have a better HRQoL than those who do [19, 20]. More
advanced postoperative treatments are now available [20], and
recently treated patients may report fewer complications and
a better HRQoL [21].
Demographic characteristics such as age, time since surgery,
comorbidity, and health status were associated with HRQoL.
Our finding that younger age was associated with worse
emotional functioning, social functioning, and future
perspectives confirms the findings of Western studies [22, 23].
Figure 3. Least-squares mean scores (adjusted for age, marital status, education, religion, employment status, menopausal status, and comorbidity) of
EORTC QLQ-BR23 and problematic proportion among the breast cancer survivors population (BP) and general population (GP). EORTC QLQ-BR23,
breast cancer module of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Problematic in functioning indicates
a score of 33 or less, and problematic in symptoms indicates a score above 66 on a scale of 0–100.
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Such age-related differences in HRQoL may result from younger
patients receiving more aggressive treatment, experiencing
greater psychological shock, possessing fewer coping strategies,
or lacking the resources necessary to manage a life-threatening
illness [22, 24].
We also observed that comorbid conditions were associated
with a significant deterioration in self-reported global HRQoL;
in physical, role, and cognitive functioning; and in future
perspectives. Our finding that physical, role, emotional, and
social functioning and future perspectives were associated with
time since surgery can be explained by the fact that most of the
limitations imposed by therapy and poor general health resolve
with time [3, 20]. In multivariate analysis, depression and
fatigue emerged as the strongest predictors of reduced HRQoL.
These findings have been reported elsewhere [24, 25] and
suggest potential intervention targets [26]. These results could
also be interpreted as suggesting that fatigue and depression
are associated with a more general tendency to complain
(i.e. they represent a trait rather than a state).
Scores for patients and the general population can be
compared in terms of either absolute or relative (percentage)
differences [14]. In the current study, both comparisons yielded
similar results, except for global HRQoL scores. It would be
important to identify target populations who have moderate to
severe limitations in functioning and symptoms and for whom
interventions would improve HRQoL [14, 27].
In this study, multivariate-adjusted analyses showed that their
sexual functioning was similar to that of women in the general
population. These findings were consistent with those of
a recent large cross-sectional study of breast cancer survivors for
whom 3 years on average had passed since diagnosis [28].
Nevertheless, younger age, menopause, and depression may be
more important risk factors for sexual dysfunction than the type
of surgery received [22, 23]. To our knowledge, no other study
has compared the body images of breast cancer survivors with
those of the general population, and we were surprised to find
that they did not differ significantly in the present study.
Although the mastectomy group had a worse body image than
general population, the BCS group reported a clinically
significant better body image than the general population,
which we did not expect. This might be understood from cancer
survivors’ developing positive attitudes from the cancer
experience [29], but more study is required to clarify this.
This study was limited by its cross-sectional design, which
restricted the generalizability of our findings to similar groups of
breast cancer survivors. Another limitation was selection bias;
our study sample may not have been representative of the
general population of women with breast cancer because it was
accrued from selected academic centers. Although there were no
major differences in sociodemographic or treatment-related
variables between the groups, the response rate was low. We may
have underestimated HRQoL problems because nonresponders
may have had a lower HRQoL. Additionally, the MQoL is
questionable as a tool for evaluating breast cancer survivors
and the general population. However, combining it with a
cancer-specific questionnaire and its breast module provided
valuable information.
In spite of its limitations, our study showed that disease-free
survivors of breast cancer had good HRQoL, which was less
affected by the type of treatment than it was by demographic
characteristics, time since surgery, comorbidity, fatigue, and
depression. This study suggests that potential intervention
targets among breast cancer survivors would include younger
survivors and those with comorbid conditions, fatigue, or
depression. Along with earlier findings from Western samples,
these results provide comprehensive information about the
long-term HRQoL effects of standard breast cancer treatments.
This information will be useful in guiding and informing the
physicians charged with making cancer-treatment decisions for
their patients because breast cancer will remain a major cause of
morbidity and mortality in Western and Asian countries into
the foreseeable future.
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